Doptelet Shortage Update: What Patients Need to Know in 2026

Patients prescribed Doptelet (avatrombopag) often search for shortage updates after struggling to obtain their medication quickly. The good news: as of 2026, Doptelet is not on the FDA's official drug shortage database. The not-so-good news: that doesn't mean it's easy to get. Here's a complete update on Doptelet availability and what it means for you.

Is Doptelet Currently in Shortage? (2026 Update)

No. Doptelet (avatrombopag) is not listed as a current drug shortage on the FDA Drug Shortage database as of 2026. AkaRx (Sobi North America), the manufacturer, has maintained consistent production. There have been no publicly reported manufacturing disruptions, facility issues, or supply chain problems affecting Doptelet.

However, Doptelet's specialty pharmacy distribution model means that even without a shortage, getting your prescription filled requires navigating a more complex process than standard medications. This is the primary source of frustration for patients.

What Is Causing Access Difficulties for Doptelet Patients?

Several non-shortage factors contribute to Doptelet access challenges in 2026:

Restricted distribution: Doptelet is only available through Doptelet network specialty pharmacies or dispensing physician practices — not at retail pharmacies.

Prior authorization delays: Insurance prior authorization typically takes 2 to 4 weeks, during which patients cannot receive their medication.

High cost without insurance: At a WAC of approximately $12,657 for 30 tablets as of 2025, Doptelet is not an affordable cash-pay option for most patients, adding another access barrier.

No generic available: Unlike many other medications, Doptelet has no FDA-approved generic, eliminating the lower-cost access route many patients rely on.

Doptelet Availability History: Has It Ever Been in Shortage?

Doptelet was first approved by the FDA in May 2018. Since then, the medication has not appeared on the FDA drug shortage list for supply-related reasons. Its distribution has been consistently managed through the specialty pharmacy network. Unlike some TPO-RAs or platelet products, Doptelet does not have a history of manufacturing shortages or FDA-mandated supply disruptions.

What Does the 2025 Pediatric Approval Mean for Supply?

In July 2025, the FDA approved Doptelet and Doptelet Sprinkle (oral granules) for pediatric patients one year and older with persistent or chronic ITP. This expanded the patient population eligible for Doptelet. While any expanded indication can increase demand, specialty drugs like Doptelet typically scale manufacturing in advance of pediatric approval. As of 2026, the pediatric approval has not triggered any reported supply constraints.

What Should Patients Do If They're Having Trouble Getting Doptelet?

If you're struggling to get Doptelet filled, the issue is almost certainly related to the enrollment or insurance process, not a drug shortage. Here are the steps to take:

Confirm your prescriber has submitted the Doptelet Connect enrollment form.

Follow up directly with the assigned specialty pharmacy on your prior authorization status.

If the PA is still pending, ask your prescriber to submit supporting clinical documentation to expedite approval.

Ask Doptelet Connect if you qualify for a free trial offer (available to new commercial-insurance patients with ITP).

Use medfinder to identify dispensing locations that currently have Doptelet and can fill your prescription.

When Could a True Doptelet Shortage Happen?

While Doptelet has not experienced supply shortages historically, patients and providers should be aware that shortages can occur with any medication. Factors that could theoretically cause a Doptelet shortage include: manufacturing facility issues at AkaRx's production sites, unexpected demand spikes from new indications, or supply chain disruptions affecting raw materials for avatrombopag synthesis. Staying enrolled in Doptelet Connect and maintaining a relationship with your specialty pharmacy is the best way to be informed early if availability changes.

Bottom Line: Doptelet Is Available — The Challenge Is Access

Doptelet is being manufactured and distributed. If you're having trouble getting it, the issue is almost certainly navigational — insurance, specialty pharmacy routing, or prior authorization. For a practical guide to solving these access challenges, see: How to Find Doptelet in Stock Near You.